Researchers freeze EBV by disrupting the cell supply chain
20 January 2016 | By Victoria White
Researchers made B-cells sense they were starving by using the drug Rapamycin, enabling them to turn the senescence of EBV-infected cells on and off...
List view / Grid view
News
Regen BioPharma and NCATS to research the NR2F6 protein
20 January 2016 | By Victoria White
The collaboration will focus on identifying ligands for NR2F6 using Regen's screening methodology and the expertise and unique chemical libraries of NCATS...
Mucosis secures €3.7m to advance its RSV vaccine, SynGEM
20 January 2016 | By Victoria White
Mucosis has secured the €3.7 million translational fund award from the Wellcome Trust to progress SynGEM into Phase I and IIa human clinical trials...
New study finds laws of nature predict cancer evolution
19 January 2016 | By Victoria White
Researchers believe that in the future, they could predict how a cancer will grow and develop by applying natural laws to single genetic snapshots taken from a cancer...
Time to renew the antibiotic arsenal
19 January 2016 | By Philippe Villain-Guillot, CEO, Nosopharm
Philippe Villain-Guillot, CEO, Nosopharm, discusses antimicrobial resistance and the challenges facing antibacterial drug discovery and development...
Rapastinel demonstrates pro-cognitive benefits in animal model of cognitive impairment
19 January 2016 | By Victoria White
Allergan has announced new data on the investigational medication rapastinel (GLYX-13) and its lack of impairment on cognitive function...
Breast cancer study reveals new drug targets and combinations
19 January 2016 | By Victoria White
The largest analysis of breast cancer cell function to date suggests dozens of new uses for existing drugs, new targets for drug discovery, and new drug combinations...
UCL announces new £50 million fund to commercialise research
18 January 2016 | By Victoria White
The Fund will be used to support academics whose research has commercial potential, with funding for early stage proof of concept, licensing projects and new spinout companies...
F-star and AbbVie to develop bispecific antibodies in immuno-oncology
18 January 2016 | By Victoria White
Under the collaboration agreement, F-star and AbbVie will create Fcabs against two immuno-oncology targets and generate several mAb2 drug development candidates from these Fcabs...
Centauri acquires Alphamer technology from Altermune
18 January 2016 | By Victoria White
Centuari has also announced that it has appointed Dr Clive Dix as Chairman and secured the first tranche of a £3M raise to develop its first lead candidate...
Channel-blocker drug helps restore vision in mice with optic nerve injury
14 January 2016 | By Victoria White
Researchers were able to restore vision in mice by using gene therapy to get the nerves to regenerate and adding a channel-blocking drug to help the nerves conduct impulses...
Calibr and Pfizer to develop heart failure therapies
14 January 2016 | By Victoria White
Calibr's antibody fusion technology provides a proprietary, modular approach to developing long-acting biotherapeutics based on peptide and protein agonists and antagonists...
Sanofi Pasteur announces support for the Human Vaccines Project
14 January 2016 | By Victoria White
The Human Vaccines Project is a research programme designed to accelerate the development of vaccines by decoding the human immune system...
Researchers discover previously unknown defect in Parkinson’s disease
13 January 2016 | By Victoria White
The discovery, made by BUSM scientists, may lead to a better understanding of the disease, early diagnosis and therapeutic development...
XBP-1 pathway plays key role in CF airway inflammation
13 January 2016 | By Victoria White
Researchers have discovered that the XBP-1 pathway was implicated in the hyper-inflammatory response of cystic fibrosis alveolar macrophages...
